IRCT20190706044111N6尚未招募未知
A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Gabapentin 300mg capsule of Alborzdarou Pharm Co., IRAN in comparison of Neurontin 300mg capsule of PFIZER in 24 healthy adult subjects under fasting condition
Alborzdarou Pharm. Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 50 years（—）
- 性别
- All
入选标准
- •Aged between 20 - 50 years
- •Body weight between 50 – 100 kg
- •Having good health on the basis of medical history and physical & clinical examination
- •Understand the procedures and give written informed consent
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Bioequivalence study of Rosuvastatin 20 mg tablet of Aburaihan Pharm Co., IRAHyperlipidemia.IRCT20190706044111N9Aburaihan Pharm Co.24
已完成
不适用
Bioequivalence study of Aristatin 10mg tablet of Arya Pharm Co., IRAHyperlipidemia.IRCT20190706044111N8Arya Pharm Company24
尚未招募
不适用
Bioequivalence study of Dexamethasone 4mg tablet of Abureihan Pharm Co., IRAInflammatory diseases.IRCT20190706044111N10Aburaihan Pharm Co.24
尚未招募
Unknown
Bioequivalence study of Famotidine 40mg tablet of Amin Pharm Co., IRAstomach ulcers.histamine H2-receptor blockersT47. 0X3IRCT20190706044111N36Amin Pharm. Co.24
招募中
不适用
Bioequivalence study of Aristatin 20mg tablet of Arya Pharm Co., IRAIRCT20190706044111N7Arya Pharm Company24